Iron, erythropoietin and vitamin C before heart surgery in iron-deficiency anemia
Tests combined iron treatment before heart surgery in iron-deficiency anemia.
Key facts
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 4 Jan 2025
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Iron sucrose, Human Erythropoietin Injection, Vitamin C
- Standard Medical Care
- Record updated
- 2 June 2026
Who can take part
The trial is looking for adults with iron deficiency anemia who are having planned major heart surgery. This includes bypass surgery (CABG), valve surgery, or both.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Iron deficiency anemia before planned major heart surgery. ASA class 1-3 (a score of general health before anesthesia).
- Earlier treatment
- No blood transfusion, intravenous iron or ascorbic acid in the 12 weeks before surgery.
- Biomarker or test result
- Ferritin below 100 μg/L, or ferritin below 300 μg/L with transferrin saturation below 25%. Hemoglobin 90 to 130 g/L for men, or 90 to 120 g/L for women.
- Main reasons for not taking part
- Emergency surgery
- Weight of 50kg (110 lb (50 kg)) or less
- Severe liver or kidney problems
- Pregnant or breastfeeding women
- Iron overload, family history of haemochromatosis or thalassaemia, or other known blood disorders
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Participants must be at least 18 years of age
- Major cardiac surgery should encompass procedures such as coronary artery bypass grafting (CABG), valve surgery, or a combination of both
- Iron deficiency anemia is defined as having a ferritin level below 100 μg/L or a ferritin level below 300 μg/L accompanied by a transferrin saturation below 25%. Additionally, hemoglobin levels should range between 90 and 130 g/L for men or between 90 and 120 g/L for women
- The American Society of Anesthesiologists (ASA) classification should fall within Grade 1-3
- Prior to participation, the patient or their legal representative must provide informed consent
Who cannot take part
- Requirement for emergency surgical intervention
- history of blood transfusion, intravenous iron or ascorbic acid use within 12 weeks prior to surgery
- Individuals with a family history of haemochromatosis or thalassaemia, or those with a transferrin saturation level exceeding 50% or a documented history of iron overload
- Presence of other known haematological disorders such as folic acid or vitamin B12 deficiency, haemolytic anaemia, haemoglobinopathies, iron granulocytic anaemia, G6PD deficiency, etc
- Acute blood loss, gastrointestinal bleeding, etc. in the preoperative period
- Severe hepatic or renal impairment, ALT >3 times the upper limit of normal value or AST >3 times the upper limit of normal value, creatinine >1.5 times the upper limit of normal value
- Contraindications for the administration of iron sucrose, ascorbic acid, or rHuEPO
- Presence of a temperature exceeding 37.5 °C or the utilization of non-prophylactic antibiotics
- Individuals with a weight equal to or less than 50kg
- Pregnant or lactating women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The trial will also look at whether this regimen is safe and well tolerated. The main questions it aims to answer are:
Read full original descriptionShow less
Does the combined regimen lower the amount of allogeneic red blood cell transfusion needed during and after surgery?
Are there any side effects or safety concerns associated with the regimen?
Researchers will compare the combined iron supplementation (sucrose iron, erythropoietin, and vitamin C) to standard care to see if it helps reduce blood transfusions.
Participants will:
Receive either the combined regimen or standard care before surgery
Undergo major elective cardiac surgery under general anesthesia
Be monitored for blood transfusion needs and recovery up to 90 days after surgery
The 2 groups in the trial
- Combined Iron Protocols group(CIP group)Treatment being tested
Preoperative randomization was conducted, followed by a three-day regimen in the week preceding surgery, involving the administration of intravenous iron sucrose at a dosage of 200 mg per day, vitamin C at a dosage of 2 g per day, and subcutaneous administration of Human Erythropoietin Injection at a dosage of 150 IU per kilogram.
Treatment: Iron sucrose, Human Erythropoietin Injection, Vitamin C
- Standard Medical Care group(SMC group)Existing treatment, for comparison
Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
Treatment: Standard Medical Care
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Iron Sucrose Combined With Human Erythropoietin and Vitamin C on Perioperative Allogeneic Red Blood Cell Infusion in Major Cardiac Surgery
- Plain-language title
- Iron, erythropoietin and vitamin C before heart surgery in iron-deficiency anemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06012760, who can take part
- Record updated
- 2 June 2026